NewsRx

Search our medical news database

Plasmodium vivax

C-Terminal Region of Surface Protein Is Immunogenic to T Cells

Published in Vaccine Weekly, June 2nd, 1997

The merozoite surface protein 1 of Plasmodium vivax (PvMSP1) is immunogenic to a large share of individuals exposed to malaria.

Although it is a potential target for vaccine development, PvMSP1 has not been studied extensively, noted Irene S. Soares and colleagues, Universidade Federal de Sao Paulo, Sao Paulo, Brazil ("Acquired Immune Responses to the N- and C-Terminal Regions of Plasmodium vivax Merozoite Surface Protein 1 in Individuals Exposed to Malaria," Infection and Immunity, May 1997;65:1606-1614).

The researchers evaluated the naturally acquired immune response to PvMSP1 in individuals with recent clinical episodes of malaria...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook